Recent interest in the New Orleans BioFund has been so high that the program has been extended through at least February 2015. Over 50 companies have approached NOBF seeking funding, and since 2013 the BioFund has dispersed over $1.5 million to local start-up companies.
January 10, 2014 – Read more at New Orleans CityBusiness
MiniVax, Inc. and the University of Rochester have entered into an exclusive option agreement to develop a monoclonal antibody for the treatment of Pneumocystis pneumonia based on research conducted at the university. Pneumocystis pneumonia is an often fatal fungal respiratory infection that affects immunocompromised patients.
January 9, 2014 – Read more at BusinessWire